Contract Award Notice - Provision of end-to-end digital histopathology pathway service with integrated AI diagnostic support and NHS reporting services

1. This is a Provider Selection Regime (PSR) Notice of Intention to make an award. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023.

This is a Notice of Intention to make an award and is being published in line with Regulation 12 - under The Health Care Services (Provider Selection Regime - PSR) Regulations 2023. The Most Suitable Provider Process shall be used to commission this service and award a contract.

2. The contract title and Reference -

Provision of end-to-end digital histopathology pathway service with integrated AI diagnostic support and NHS reporting

The contract reference - C407455

3. The name and address of the registered office or principal place of business of the provider to whom the contract has been awarded -

Inify Laboratories Ltd

191c Nebula

Park Drive

Milton Park

Oxfordshire

England

OX14 4SE

4. A description of the relevant health care services to which the contract relates, including the most relevant CPV code -

Inify delivers a fully integrated, co-designed diagnostic service that aligns with NHS pathways, enables seamless information sharing, and strengthens multidisciplinary collaboration. Its resilient, scalable, and digitally enabled model ensures long-term service continuity and robust governance

85111800 - Pathology services

5. The lifetime value of the contract or, where it is not known, the amounts payable to the provider under the contract -

£275000

6. Details of the award decision-makers -

Rob Archer (Cellular & Anatomical Pathology Operations Manager), Mark Austin (Category Manager for Clinical Support)

7. A statement explaining the award decision-makers’ reasons for selecting the chosen provider, with reference to the key criteria -

Based on our assessment against PSR criteria, we believe Inify Laboratories is the only provider capable of delivering the required service for the following reasons:

• End-to-End Integrated Diagnostic Pathway: Inify offers a fully digital, AI-supported histopathology service covering the entire prostate cancer diagnostic workflow—from biopsy logistics to final reporting—within a unified digital ecosystem.
• Immediate Access to a Complete Digital Solution: Their platform is fully paperless and interoperable from day one, regardless of the Trust’s existing digital infrastructure.
• Specialist Focus and Proven Expertise: Inify is purpose-built for prostate cancer diagnostics, with 2.5 years of proven experience in Sweden, delivering faster and more accurate diagnoses compared to generalist labs.
• AI-Enhanced Accuracy and Efficiency: Validated AI tools significantly reduce diagnostic variation and improve turnaround times (average 3.5 days), supporting NHS reporting targets.
• ISO 15189 Accredited Digital Lab: Inify operates a fully standardised, controlled laboratory with embedded AI and an in-house LIMS, ensuring quality and compliance at scale.
• Alignment with NHS Objectives: The service directly supports the NHS Histopathology Improvement Plan and National Cancer reporting targets, while improving workforce efficiency and patient experience

8. Any declared conflicts or potential conflicts of interest -

No declared conflicts of interest

9. Information as to how any conflicts or potential conflicts of interest were managed -

Decision makers have completed and signed conflicts of interest declarations prior to commencing the process (no conflicts declared).

Supplier details as published

Taken from this notice, not from Companies House. Check the original notice — details change and are not updated here.

Lots

This procurement was divided into 1 lots, each awarded separately.

Tender Documents

• Transparency notice on Find a Tender → — Award notice